SAN MARINO, Calif.--(BUSINESS WIRE)--

Viral Genetics, Inc. (Pinksheets: VRAL.PK - News) today announced that Nathan Tinker, PhD, has joined the company’s list of industry-leading advisors. This represents the next step in the Company’s 2012 plan to reach out to potential industry partners in order to enhance corporate development and capital-raising capabilities.

Nathan Tinker, currently Executive Director of the New York Biotechnology Association (NYBA), has built his career in the life sciences and nano-sciences sectors. NYBA is a not-for-profit trade association promoting the development and growth of bioscience related industries and institutions in New York State. The organization promotes cooperation between academia and industry, and new and established companies, including making specialists from larger member companies available to offer assistance with early-stage ventures. Before joining NYBA, Nathan led the Sabin Vaccine Institute’s Cancer Vaccine Consortium and was a co-founder of the NanoBusiness Alliance (now the NanoBusiness Commercialization Association).

“We are very pleased to add Nathan as a corporate development advisor to our team where we believe he will add a great deal of value by focusing the marketing of both our drug and biofuel technologies to potential strategic partners,” said Haig Keledjian, President of Viral Genetics and VG Energy.

“Viral Genetics and VG Energy provide the strategic partnering marketplace with some of the most interesting science and technology opportunities that I have encountered in an emerging company. The two core technologies are exactly the types of assets that potential industry partners are seeking: they are platform technologies offering a number of potential product development opportunities in major markets and not just 'one-trick ponies;' the intellectual property securing them is well-established through a series of patents and patent applications; and they hold the promise of offering significant advances to their respective end-markets – novel mechanisms of disease treatment and advanced biofuels,” said Nathan Tinker.

About Viral Genetics, Inc.

San Marino, California-based Viral Genetics discovers drug therapies from two platform technologies based on over 60 patents: Metabolic Disruption (MDT) and Targeted Peptides (TPT). Founded in 1994, the biotech company is researching treatments for HIV/AIDS, Lyme Disease, Strep, Staph and drug resistant cancer. A majority-owned subsidiary, VG Energy (www.vgenergy.net), is dedicated to exploring biofuel and agricultural applications for the MDT platform. For more information, visit http://www.viralgenetics.com.

About VG Energy

VG Energy Inc. is an alternative energy and agricultural biotech company that is a majority-owned subsidiary of Viral Genetics Inc. Using its Metabolic Disruption Technology (MDT), Viral Genetics' cancer research led to discoveries with major consequences in a wide variety of other industries, including production of biofuel and vegetable oils. VG Energy holds the exclusive worldwide license to the MDT patent rights for use in the increase of production of various plant-derived oils from algae and seeds. Application of MDT technology to the biofuel industry could potentially allow it to overcome its major obstacle in the area of production efficiency: namely, an increase in production yields leading to feasible economic returns on investment, allowing renewable biodiesel to be competitive with fossil fuels. For more information, please visit http://www.vgenergy.net.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS:

This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical trials, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports, including statements about its VG Energy, Inc. subsidiary. None of Viral Genetics' drug compounds are approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world, nor are any non-pharmaceutical products of VG Energy, Inc. commercialized. While Viral Genetics believes that the forward-looking statements and underlying assumptions reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Viral Genetics to establish the efficacy of any of its drug therapies in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of those drug compounds in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests including clinical trials on time or at all, the successful outcome of such studies or tests, or the successful commercialization of VG Energy, Inc.’s non-pharmaceutical products. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by Viral Genetics or any other person that the objectives and plans of Viral Genetics will be achieved.

See the original post here:
Viral Genetics Inc. Adds Nathan Tinker to Corporate Development Advisory Board

Comments are closed.